IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a private biotech revolutionizing cellular secretome therapies to address age and disease-related immune decline, is thrilled to announce its selection as a finalist for the Best of America Small Business Awards (BASA). The BASA awards celebrate the resilience, creativity, and indispensable role that small businesses play in enhancing economic growth and social responsibility.
There are approximately 33 million businesses in the US, with 99.9% of them being small businesses that rarely receive the recognition of their large corporation counterparts. BASA is one of the few independent awards with a select panel of judges and third-party industry experts to showcase the best small businesses for their innovative contributions.
As Immunis advances to the next round of the competition, the public’s participation becomes paramount. A public voting round from October 23rd through Nov 3rd allows supporters and advocates of Immunis to play a crucial role in the decision-making process of the award winners. We encourage everyone to cast their vote for Immunis. Your support will not only bolster our chances of winning but also serve as a powerful reminder of the community’s belief in our mission and values. Please VOTE HERE!!!
Dr. Hans Keirstead, Chairman of Immunis, expressed how being selected as finalists “reflects the passion, dedication, and innovation that every member of our team contributes to Immunis. We are not just a company; we are a community of individuals dedicated to making a difference, and this recognition validates our efforts to propel us forward.”
Let’s celebrate excellence by voting for Immunis as one of the best small businesses in America!
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
